Synonyms: CKD-732 [2] | O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol | ZGN 440 | ZGN-440
Compound class:
Synthetic organic
Comment: Beloranib is an investigational drug candidate for the treatment of obesity. The compound is a synthetic derivative of the antimicrobial agent fumagillin, from Aspergillus fumigatus. Beloranib is administered by subcutaneous injection.
|
|
References |
1. Chun E, Han CK, Yoon JH, Sim TB, Kim YK, Lee KY. (2005)
Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer, 114 (1): 124-30. [PMID:15523682] |
2. Joharapurkar AA, Dhanesha NA, Jain MR. (2014)
Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes, 7: 73-84. [PMID:24611021] |
3. Kim YM, An JJ, Jin YJ, Rhee Y, Cha BS, Lee HC, Lim SK. (2007)
Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol, 38 (4): 455-65. [PMID:17446235] |
4. Lee HS, Choi WK, Son HJ, Lee SS, Kim JK, Ahn SK, Hong CI, Min HK, Kim M, Myung SW. (2004)
Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. Arch Pharm Res, 27 (2): 265-72. [PMID:15029870] |
5. McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, Chan CL, Stafford D, Abuzzahab MJ, Viskochil D et al.. (2017)
Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab, 19 (12): 1751-1761. [PMID:28556449] |
6. Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim DH et al.. (2012)
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Invest New Drugs, 30 (2): 672-80. [PMID:21188464] |
7. Yin SQ, Wang JJ, Zhang CM, Liu ZP. (2012)
The development of MetAP-2 inhibitors in cancer treatment. Curr Med Chem, 19 (7): 1021-35. [PMID:22229417] |